Evidence map›Paper›PMID 21646283›Full record

ArticleEuropean journal of endocrinology2011

Liraglutide as additional treatment for type 1 diabetes.

Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01722266 (Liraglutide in the Treatment of Type 1 Diabetes Mellitus), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01722266 phase3completedstarted 2012, after this paper: background citation

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Ran2012Enrolled72Registered outcomes7Posted comparisons0ConditionsType 1 DiabetesArmsliraglutide, Placebo
PMID 20404854PMID 20109994PMID 21856595PMID 23807520PMID 17379054PMID 20019672PMID 17180352PMID 20841306PMID 18996824PMID 20207828PMID 19808924other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 129 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Exenatide exerts a potent antiinflammatory effect.The Journal of clinical endocrinology and metabolism · 2012 · on this map
    Trial
  11. Review
  12. Article
  13. Review
  14. The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Review
  15. Adjunctive therapy for glucose control in patients with type 1 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ajay VaranasiDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, 3 Gates Circle, Buffalo, New York 14209, USA.
Natalie Bellini
Deepti Rawal
Mehul Vora
Antoine Makdissi
Sandeep Dhindsa
Ajay Chaudhuri
Paresh Dandona
University at Buffalo, State University of New York · USKaleida Health · US

Funding

Testosterone effects on insulin sensitivity & inflammation in T2DM and obesityR01DK075877 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DANDONA, PARESH · 2009 to 2012
$2.3M
Inflammation in obesity: Modulation by Weight LossR01DK069805 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DANDONA, PARESH · 2005 to 2009
$1.5M
NIDDK NIH HHS R01DK069805-02NIDDK NIH HHS R01DK075877-01-A2
6 · The paper itself

Abstract

objectiveTo determine whether the addition of liraglutide to insulin to treat patients with type 1 diabetes leads to an improvement in glycemic control and diminish glycemic variability. SUBJECTS AND

methodsIn this study, 14 patients with well-controlled type 1 diabetes on continuous glucose monitoring and intensive insulin therapy were treated with liraglutide for 1 week. Of the 14 patients, eight continued therapy for 24 weeks.

resultsIn all the 14 patients, mean fasting and mean weekly glucose concentrations significantly decreased after 1 week from 130±10 to 110±8  mg/dl (P<0.01) and from 137.5±20 to 115±12  mg/dl (P<0.01) respectively. Glycemic excursions significantly improved at 1 week. The mean s.d. of glucose concentrations decreased from 56±10 to 26±6  mg/dl (P<0.01) and the coefficient of variation decreased from 39.6±10 to 22.6±7 (P<0.01). There was a concomitant fall in the basal insulin from 24.5±6 to 16.5±6 units (P<0.01) and bolus insulin from 22.5±4 to 15.5±4 units (P<0.01). In patients who continued therapy with liraglutide for 24 weeks, mean fasting, mean weekly glucose concentrations, glycemic excursions, and basal and bolus insulin dose also significantly decreased (P<0.01). HbA1c decreased significantly at 24 weeks from 6.5 to 6.1% (P=0.02), as did the body weight by 4.5±1.5  kg (P=0.02).

conclusionLiraglutide treatment provides an additional strategy for improving glycemic control in type 1 diabetes. It also leads to weight loss.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 1FemaleGlucagon-Like Peptide 1Glycated HemoglobinHumansHypoglycemic AgentsInsulinLiraglutideMaleWeight LossBlood GlucoseGlucagon-Like Peptide 1Glycated HemoglobinHypoglycemic AgentsInsulinLiraglutide

Identifiers

PMID21646283
OpenAlexW2104788765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.